EXPLORING THE POTENTIAL OF VENOMOUS COMPOUNDS: SNAKE AND SCORPION VENOMS IN CANCER THERAPY

Snake and scorpion venoms are complex mixtures of bioactive molecules, including enzymes, peptides, and proteins, that have demonstrated significant therapeutic potential, particularly in the development of anticancer treatments. Both venoms contain components with cytotoxic, apoptotic, and anti-metastatic properties, making them promising candidates for cancer therapy. Snake venom toxins, such as phospholipases A2, disintegrins, and crotoxin, have shown the ability to inhibit tumor cell proliferation, induce apoptosis, and disrupt critical molecular pathways involved in cancer progression. Scorpion venom, with its diverse peptides like chlorotoxin, has been studied for its selective binding to tumor cells, inhibition of cell migration, and anti-angiogenic effects, particularly in solid tumors. Additionally, components from both venoms have exhibited immune-modulatory activities, enhancing the body’s natural defenses against cancer. Despite the promising preclinical results, clinical translation remains a challenge due to the need for optimizing venom components, evaluating toxicity, and determining effective doses. Nevertheless, the potential of snake and scorpion venoms in anticancer drug development represents an exciting area of research, offering the possibility of novel and targeted therapies for various cancers. Continued studies are essential to explore their full therapeutic potential and pave the way for clinical applications.